Addus HomeCare (ADUS) Expected to Announce Quarterly Earnings on Monday

Addus HomeCare (NASDAQ:ADUS) is projected to issue its Q2 2025 quarterly earnings data after the market closes on Monday, August 4th. Analysts expect the company to announce earnings of $1.45 per share and revenue of $345.71 million for the quarter.

Addus HomeCare (NASDAQ:ADUS) last announced its quarterly earnings results on Monday, May 5th. The company reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.33 by $0.09. The business had revenue of $337.71 million for the quarter, compared to the consensus estimate of $341.66 million. Addus HomeCare had a net margin of 6.52% and a return on equity of 9.23%. Addus HomeCare’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same period last year, the company posted $1.21 EPS. On average, analysts expect Addus HomeCare to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Addus HomeCare Stock Performance

Shares of NASDAQ:ADUS opened at $104.96 on Friday. The firm’s 50 day simple moving average is $111.90 and its 200 day simple moving average is $108.79. Addus HomeCare has a fifty-two week low of $88.96 and a fifty-two week high of $136.72. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.74 and a quick ratio of 1.74. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of 23.69, a P/E/G ratio of 1.51 and a beta of 0.80.

Insider Buying and Selling at Addus HomeCare

In related news, EVP Michael D. Wattenbarger sold 2,045 shares of the firm’s stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $115.00, for a total value of $235,175.00. Following the completion of the transaction, the executive vice president directly owned 7,796 shares of the company’s stock, valued at approximately $896,540. This trade represents a 20.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Addus HomeCare

Hedge funds and other institutional investors have recently made changes to their positions in the company. Royal Bank of Canada grew its stake in shares of Addus HomeCare by 24.3% in the first quarter. Royal Bank of Canada now owns 6,899 shares of the company’s stock valued at $682,000 after buying an additional 1,347 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Addus HomeCare by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,374 shares of the company’s stock valued at $1,026,000 after buying an additional 459 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Addus HomeCare by 387.6% in the first quarter. Jane Street Group LLC now owns 11,045 shares of the company’s stock valued at $1,092,000 after buying an additional 8,780 shares in the last quarter. Intech Investment Management LLC grew its stake in shares of Addus HomeCare by 44.7% in the first quarter. Intech Investment Management LLC now owns 14,362 shares of the company’s stock valued at $1,420,000 after buying an additional 4,439 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Addus HomeCare by 6.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 51,679 shares of the company’s stock valued at $5,111,000 after buying an additional 2,952 shares in the last quarter. 95.35% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. JMP Securities reissued a “market outperform” rating and set a $150.00 target price on shares of Addus HomeCare in a research note on Wednesday, July 16th. Macquarie reissued an “outperform” rating and set a $133.00 target price on shares of Addus HomeCare in a research note on Tuesday, June 10th. Finally, Wall Street Zen raised Addus HomeCare from a “hold” rating to a “buy” rating in a research note on Sunday, June 29th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $142.57.

Addus HomeCare Company Profile

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.